The role of fibroblast growth factor 2 in patients with uterine smooth muscle tumors: an immunohistochemical study

详细信息    查看全文

• 作者：Barbara Bodner-Adler^a ; ^{Barbara.Bodner-Adler@meduniwien.ac.at} ; Klaus Mayerhofer^a ; Klaus Czerwenka^b ; ¹ ; Oliver Kimberger^c ; ^d ; Heinz Koelbl^a ; Klaus Bodner^a
• 关键词：FGF-2 expression ; Uterine smooth muscle tumors ; Immunohistochemistry ; Clinicopathologic parameters ; Prognosis
• 刊名：European Journal of Obstetrics & Gynecology and Reproductive Biology
• 出版年：2016
• 出版时间：December 2016
• 年：2016
• 卷：207
• 期：Complete
• 页码：62-67
• 全文大小：505 K
• 卷排序：207

文摘

Fibroblast growth factor 2 (FGF-2) is considered to be a potent stimulator of angiogenesis and seems therefore to play an important role in the growth of tumors. We compared the immunohistochemical profile of FGF-2 in patients with uterine leiomyomas, smooth muscle tumors of uncertain malignant potential (STUMP) and leiomyosarcoma (LMS). Furthermore, we tried to clarify the prognostic role of FGF-2 in uterine leiomyosarcoma.Study designFGF-2 expression was investigated by immunohistochemistry from paraffin-embedded tissue in 26 patients with leiomyoma, in 24 cases with STUMP and in 21 patients with LMS. The immunohistochemical profile of these 3 tumor entities was compared and regarding LMS correlated with different clinicopathologic parameters.ResultsFGF-2 was expressed in 85% of leiomyomas, in 88% of STUMP and in 57% of LMS. Significant differences regarding the frequency of FGF-2 expression were observed between leiomyoma and LMS as well as between STUMP and LMS (p < 0.05). In uterine LMS FGF-2 expression was statistically more frequent in cases with high histological grade (p < 0.05). Furthermore, FGF-2 positive tumors demonstrated a statistically significant higher rate of recurrence disease and tumor progression (p = 0.005). Disease free as well as overall survival was significantly shortened in patients with FGF-2 positive compared to FGF-2 negative tumors (p < 0.05).ConclusionThe significant correlation between FGF-2 expression and high histological grade indicates that FGF-2 might work as a negative predictive factor. Higher rates of recurrence disease as well as shortened disease free and overall survival among FGF-2 positive LMS support the potential role as prognosticator for poor clinical outcome.